Calcitriol – promising chemopreventive agent that may prevent prostate cancer The active metabolite of vitamin D, calcitriol, and other vitamin D analogs are promising chemopreventive agents that may prevent prostate cancer, according to a study presented today at the American Association for Cancer Research’s 4th annual Frontiers in Cancer Prevention Study meeting in Baltimore. Researchers from Roswell Park Cancer Institute carried out both in vitro and in vivo studies to look for the ramifications of calcitriol and the analogs, QW-1624-F2-2 and paricalcitol, on the prevention of prostate cancer. Calcitriol is the active metabolite of vitamin D, and can be used clinically to treat a variety of disorders, including recent clinical trials for established malignancy traitement cialis quotidien .
However, individuals using non-protocol supplements at entry reported less joint discomfort weighed against those in the placebo group. The influence of calcium and vitamin D supplementation separately on joint symptoms had not been determined because both were provided combined in a single pill in this trial. Dr. Chlebowski concludes, ‘Joint symptoms are relatively common in postmenopausal women. Nevertheless, daily supplementation with 1,000 mg of calcium carbonate and 400 IU of vitamin D3 in a randomized, placebo-controlled clinical trial setting did not reduce the self-reported regularity or severity of joint symptoms.’ Dr. Chlebowski and his team add these findings do not speak against current recommendations for vitamin D intakes for bone health and fracture risk reduction..